Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for certain types of carcinoma.

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

It's unclear whether tariffs will influence more companies to make more drugs in the U.S. like President Donald Trump is ...

Ericsson joining Avanci Video as a licensor and the EUIPO's plans for AI use were also among the top talking points this week ...

Cipla rallied 3.80% to Rs 1,470.15 after the firm received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Paclitaxel, a generic ...

Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated ...

Elara had already factored in approximately $20 million in revenue from gAbraxane in the US for FY26. While 3–4 generic ...

Bristol Myers Squibb Co. closed 20.32% short of its 52-week high of $63.33, which the company achieved on March 11th.

With data as of April 9, 2025, we examine if Bristol-Myers Squibb Company(BMY) is consistently building momentum based on ...

Bristol-Myers Squibb Company (BMY) is currently at $50.78, down $2.96 or 5.5% --Would be lowest close since Sept. 26, 2024, when it closed at $50.12 --On pace for largest percent decrease since April ...

Bearish flow noted in Bristol Myers ( BMY) Squibb with 7,624 puts trading, or 1.4x expected. Most active are 5/2 weekly 50 puts and May-25 65 calls, with total volume in those strikes near 5,500 ...

The threat of tariffs has put the pharma industry through the wringer this week. On Wednesday, a week after instituting widespread tariffs and a day after promising that “major” tariffs were headed ...